ImmuOne
A spin-out company from the University of Hertfordshire, specialising in human in vitro cell culture solutions for safety assessment.Contact Form
The ImmuOne technology allows for the respiratory testing of any sort of chemical or particles that we might inhale. Scientists and researchers can use the test results to measure the extent of the damage that these substances can cause and determine the concentration that might be considered safe. This has worthwhile potential applications across a range of industries relating to pollution, agricultural chemicals, asthma, paint inhalation, as well as minimising the use of animal testing
2019
Start Date
Hatfield
Location
7
Employees
£450k
Grants
£100k
Equity
The Journey
“I think it was about halfway through ICURe when we started having conversations, that we realised what a gap in the market there was for this technology. The problems in the industry as it stands had actually been solved academically, but the bridge back to the market had never been connected. That was the point that I got really excited, and it just took off from there. At the Options Roundabout I could barely contain myself – I was so excited to tell the team what I had found out. When I started on ICURe I didn’t have any real expectations of my technology, so I was blown away to discover just how in demand it was. ICURe gave me the opportunity to speak to more people than I ever would have been able to on my own. It also helped us to identify three other market sectors – one of which is now our main target market.”
Abigail Martin, Co-Founder ImmuONE
Took part in ICURe £35k
ICURe roundabout success £15k
Innovate UK commercialisation project activated
First investment received £100k
£600k NC3Rs grant received
About to close £1.5m investment round
What companies had to say about the ICURe programme?
I certainly couldn’t have foreseen that less than two years after completing the programme we would be spinning out, and developing the product even further, with a team of employees. ICURe was absolutely essential to this process, and to us becoming the company we are today.
Abigail Martin
Co-Founder ImmuONE
Future Goals
The future is looking very bright for us at the moment. Our technology is a game-changer for a number of industries, including drug development, the cosmetic industry and pharmaceuticals. In pharmaceuticals, for example, there haven’t been any new drugs developed for the past 15-20 years, despite the fact asthma and other respiratory disorders are so prevalent now. Due to pollution and all these additional chemicals that we’re inhaling, I think often we forget that we take 23,000 breaths a day. To know what we’re developing is going towards making each of those breaths safer for our bodies is an incredible place to be.
